Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Colgate-Palmolive

Walmart

Dividend stocks are my favored way for generating passive income for retirement. Passive income is generated with minimal effort once set up, and can snowball beautifully as dividends are reinvested. Not all Dividend Aristocrats are good for a massive dividend snowball, here are 3 I wouldn't own.

Sell Alert: 3 Dividend Aristocrats That May Kill Your Passive Income Snowball

McDonald's

UnitedHealth Group

While investors often overlook the Dow Jones Industrial Average in favor of the S&P 500 and the Nasdaq 100, the Dow comprises some of the highest-quality businesses in the world. The top Dow stocks to buy represent a broad spectrum of industries and are known for their stability, resilience, and potential for steady growth.

The 3 Smartest Dow Stocks to Buy With $1000 Right Now

Kenvue

Rexford Industrial Realty

FOMO is driving stock market decisions, especially with meme stocks like GameStop and high-flying AI stocks. That's why I prefer discounted dividend stocks over growth stocks, and highlight two picks that offer durable capital returns. Both names carry strong balance sheets, pay well-above market average dividend yields, and are trading at substantial discounts to their historical valuations.

Two High Conviction Dividend Buys For This Upside-Down Market

Bristol-Myers

Pfizer

Pfizer has a lot of new drugs on the market, but its stock has been beaten down. Johnson & Johnson stock is down even though both its medical technology and pharmaceutical businesses reported significant gains this year.

3 High-Yield Dividend Stocks Near Their 52-Week Lows to Buy and Hold

Costco

These dividend stocks have different business models, but each has something to lend to a long-term investor's portfolio. Johnson & Johnson is focusing on the next era of growth, and its strategy is working.

2 Top Stocks to Buy Now for Years of Passive Income

J&J (JNJ) seeks label expansion for Tremfya for treating moderately to severely active Crohn's disease. This marks the second sBLA filing for Tremfya in three months.

J&J (JNJ) Seeks Expanded Use of Tremfya for Crohn's Disease

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) announced today that it has successfully completed the acquisition of Proteologix, Inc., a privately-held biotechnology company focused on bispecific antibodies for immune-mediated diseases, for $850 million in cash with potential for an additional milestone payment, as announced on May 16, 2024. “We look forward to continuing the development of PX-128 and PX-130 alongside the Proteologix team as they join Johnson & Joh.

Johnson & Johnson Completes Acquisition of Proteologix, Inc.

Submission is supported by 48-week results from the Phase 3 GALAXI and GRAVITI programs TREMFYA® is the only IL-23 inhibitor to demonstrate strong endoscopic outcomes with subcutaneous (SC) induction, consistent with intravenous (IV) induction, and has the potential to be the first in its class to offer the option of both SC and IV induction therapy in Crohn's disease GALAXI includes data demonstrating superior outcomes for TREMFYA® versus STELARA® (ustekinumab) in Crohn's disease SPRING HOUSE, Pa. , June 20, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of TREMFYA® (guselkumab) for the treatment of adults with moderately to severely active Crohn's disease.

Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment of moderately to severely active Crohn's disease

TRENTON, N.J.--(BUSINESS WIRE)--Some of the nation's largest law firms recognized for their committed and successful representation of individuals harmed by dangerous products have announced unified opposition to a plan by Johnson & Johnson to seek a prepackaged bankruptcy to address claims brought by ovarian cancer victims. Two previous bankruptcy filings by the company, which has a market value of more than $350 billion, have been denied by federal courts in New Jersey where J&J is he.

More than 60 Law Firms Oppose J&J Prepack Bankruptcy Scheme

Cardinal Health

Caterpillar

Deere & Company

PayPal

Buybacks are in fashion. But at today's valuations, companies could be paying up for their own stock—and that's never a good idea, whether you're a CEO or a retail investor.

5 Cheap Stocks Buying Back Shares at Reasonable Prices

TREMFYA® Phase 3 Crohn's disease study achieves all primary and secondary endpoints SPRING HOUSE, Pa. , June 20, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced positive topline results from the pivotal Phase 3 GRAVITI investigational study of TREMFYA® (guselkumab) subcutaneous (SC) induction therapy in adult patients with moderately to severely active Crohn's disease.1 The study met both co-primary endpoints, achieving statistically significant and clinically meaningful outcomes for clinical remission at Week 12 as well as endoscopic response at Week 12.

TREMFYA® (guselkumab) studies underscore its potential to be the only IL-23 inhibitor to offer both subcutaneous and intravenous induction

AbbVie

British American Tobacco

Disney

JPMorgan Chase & Co

Starbucks

While investing, the focus is on the top blue-chip stocks to buy that offer growth with stability. It is vital to comprehend the fundamentals that characterize these superior stocks.

7 High-Value Blue-Chip Stocks to Boost Your Wealth by 2027

Anheuser-Busch InBev

Federal Realty Investment Trust

While getting to retirement age can be a blessing and a curse, the reality of counting on the U.S.

5 Dividend Kings to Buy Now for Dependable Retirement Passive Income

iShares S&P 500 Value ETF

iShares S&P 500 Growth ETF

In a challenging market, I recommend a defensive strategy focused on quality stocks at deep-value prices. High S&P 500 valuations suggest subdued returns, emphasizing cautious investing. The AI-driven rally has skewed expectations, benefiting a few stocks. Despite early underperformance, I believe in the long-term potential of value investing based on historical trends. Focus on companies with strong fundamentals, consistent dividends, and growth potential. This approach offers stability and outperformance in a demanding investment landscape.

Buying Value The Smart Way - 3 Fantastic Dividend Stocks To Buy Now

In the latest trading session, Johnson & Johnson (JNJ) closed at $145.65, marking a -0.21% move from the previous day.

Johnson & Johnson (JNJ) Stock Falls Amid Market Uptick: What Investors Need to Know

Johnson & Johnson is facing a new proposed class action seeking damages and medical monitoring on behalf of women who have been diagnosed with cancer, or might develop it in the future, allegedly as a result of using the company's baby powder and other talc products.

J&J hit with new class action over talc seeking medical monitoring for cancer

Novo Nordisk

Pinduoduo Inc - ADR

As markets continue to reach new all-time highs, investors are constantly seeking opportunities that offer both stability and growth potential. With the S&P 500 and Nasdaq recently hitting new all-time highs, investors are out bargain hunting.

3 Mega Cap Stock Bargains As Markets Hit All-Time Highs

TRENTON, N.J.--(BUSINESS WIRE)--Plaintiffs who are at increased risk of ovarian cancer due to long-term use of Johnson & Johnson's Baby Powder have filed a class action lawsuit in New Jersey federal court seeking to hold Johnson & Johnson (NYSE:JNJ) and a number of corporate subsidiaries and executives responsible for future liability and to establish a court-supervised system to monitor the ongoing health condition of talcum powder users. The proposed class action alleges that the defe.

Beasley Allen and Levin Papantonio: Leading Law Firms Seek Protection for Future Victims of Johnson & Johnson Talc Products

Application based on Phase 3 PALOMA-3 results showing five-fold reduction in infusion-related reactions with five-minute administration of subcutaneous amivantamab Longer overall survival, progression-free survival and duration of response also observed with subcutaneous amivantamab RARATIN, N.J., June 17, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for a fixed combination of amivantamab and recombinant human hyaluronidase for subcutaneous administration (SC amivantamab) for all currently approved or submitted indications of intravenous (IV) RYBREVANT® (amivantamab-vmjw) in certain patients with non-small cell lung cancer (NSCLC).

Subcutaneous amivantamab Biologics License Application submitted to U.S. FDA for patients with EGFR-mutated non-small cell lung cancer

Accenture Plc

Blue-chip stocks are synonymous with stability and reliability. Investors search amongst these names to find companies with long track records of strong performance, healthy financials and established market presence.

Blue-Chip Jackpots: 3 Top-Notch Stocks at Bottom-Barrel Prices

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?

Johnson & Johnson (JNJ) Could Be a Great Choice

24-month overall survival rate of 67 percent achieved with TALVEY® 0.8 mg/kg biweekly dosing in the Phase 1/2 MonumenTAL-1 study MADRID , June 14, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that long-term data from the Phase 1/2 MonumenTAL-1 study showed that with 20 to 30 months of median follow-up, triple-class-exposed patients with relapsed or refractory multiple myeloma (RRMM) who were treated with TALVEY® (talquetamab-tgvs) maintained high overall response rates (ORR) and durable responses, irrespective of whether they had received prior T-cell redirection therapy. 1  These data, featured in a poster presentation at the 2024 European Hematology Association (EHA) Congress (Abstract #P915) demonstrate the efficacy and durability of TALVEY® when used before or after chimeric antigen receptor T-cell (CAR-T) therapy or bispecific antibody therapies in triple-class-exposed patients with RRMM.1  "Results from the MonumenTAL-1 study continue to show deeper response levels and a longer duration of response in patients treated with either of the approved dose options of talquetamab, while the median overall survival has yet to be reached at two years," said Dr. Leo Rasche, attending physician on the myeloma service, University Hospital of Würzburg.

TALVEY® (talquetamab-tgvs) demonstrates highly durable, longer-term responses in patients with relapsed or refractory multiple myeloma

B2Gold

Duke Energy

Philip Morris

Shell PLC

Target

Just like in arguably most sports, balance is everything. The same applies to dividend stocks to buy.

Payout Powerhouses: 7 Dividend Stocks to Buy Now

Agree Realty

Altria

Building a solid retirement portfolio to carry you through your golden years requires just a few key ingredients like income reliability, dividend growth and exceptional yield. That's because retirement is not the time to take fliers on penny stocks.

News for Johnson & Johnson Stock (JNJ)